TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02459938
Drug: Glucagon (ZP-Glucagon)
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
Study: NCT02459938
Drug: Glucagon (GlucaGen)
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant glucagon administered via subcutaneous injection
Study: NCT03740373
Drug: BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
Normalized name: calcium chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
Study: NCT04222062
Drug: Carmustine 7.7Mg Wafer
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
Study: NCT00556192
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period.
Study: NCT02535273
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
Study: NCT03740373
Drug: BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold
Normalized name: (S)-3-Isobutyl GABA
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
Study: NCT02535273
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
Study: NCT02535273
Drug: Low-dose Dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
Study: NCT03691727
Drug: tirofiban hydrochloride (AGGRASTAT®)
Normalized name: tirofiban Injection [Aggrastat]
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
Study: NCT01108627
Drug: foradil
Normalized name: Foradil
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: open-labeled inhaled corticosteroids (ICS); foradil
Study: NCT00494962
Drug: lecozotan SR
Normalized name: Lecozotan
DrugBank: Lecozotan (DB12540)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02732262
Drug: Oxycodone, 1.00 mg dose
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
Study: NCT02732262
Drug: Oxycodone, 0.03 mg/kg dose
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
Study: NCT02732262
Drug: Oxycodone, 0.02 mg/kg dose
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
Study: NCT02535273
Drug: Moderate-dose Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
Study: NCT02535273
Drug: High-dose Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
Study: NCT02285374
Drug: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
Study: NCT00006760
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V over 24 hours on days 1-4
Study: NCT00006760
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV over 6-10 minutes on days 1 and 5.
Study: NCT00468364
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03927950
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: escitalopram 10-20mg per day 12 weeks
Study: NCT03927950
Drug: bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion 150-300mg per day 6 weeks
Study: NCT03945188
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Study: NCT01515410
Drug: DM-1992
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 72.5mg carbidopa/230mg levodopa
Study: NCT02219048
Drug: PF-03715455
Normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
Study: NCT04410198
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Study: NCT01016210
Drug: Leuveris
Normalized name: Luveris
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01016210
Drug: Leuveris
Normalized name: Luveris
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
Study: NCT02015676
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
Study: NCT02015676
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
Study: NCT02015676
Drug: Myocet
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
Study: NCT04794803
Drug: Reparixin
Normalized name: Reparixin
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
Study: NCT01250977
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04161508
Drug: Sugammadex Injection
Normalized name: sugammadex Injection
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
Study: NCT04161508
Drug: Neostigmine Injection
Normalized name: neostigmine Injectable Solution
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
Study: NCT00423176
Drug: MFNS and antibiotic
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
Study: NCT00423176
Drug: Matching Placebo nasal spray plus antibiotic
Normalized name: oxymetazoline Nasal Spray [Duramist Plus]
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
Study: NCT02871648
Drug: Fludrocortisone
Normalized name: Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 0.1 mg
Study: NCT03629184
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.
Study: NCT03629184
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
Study: NCT01590303
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
Study: NCT00972595
Drug: ondansetron clinical trial formulation
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
Study: NCT00972595
Drug: ondansetron marketed formulation
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
Study: NCT01461538
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
Study: NCT01461538
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.4 mg/kg every 3 weeks by intravenous (IV) infusion
Study: NCT01461538
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
Study: NCT01884038
Drug: treprostinil sodium
Normalized name: Treprostinil Sodium
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative
Study: NCT01263938
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day.
Study: NCT03476538
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are tested for their normal prescription gabapentin medication
Study: NCT01587508
Drug: cyclobenzaprine - Miosan®
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two oral tablet a day during approximately 07 days
Study: NCT00191607
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02729909
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone capsules
Study: NCT01971047
Drug: Humalog
Normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 2 treatment arm. Follow dosing for Blood glucose \> 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose
Study: NCT04597697
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
Study: NCT00368797
Drug: XRP0038 (NV1FGF)
Normalized name: NV1FGF
DrugBank: Riferminogene pecaplasmid (DB06394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00699998
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
Study: NCT00699998
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
Study: NCT00699998
Drug: Commercially-available Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose aspirin, oral, as prescribed by physician through end of study
Study: NCT02660905
Drug: Ledipasvir-Sofosbuvir
Normalized name: Ledipasvir-Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Study: NCT01321827
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
Study: NCT00329082
Drug: LY2062430
Normalized name: LY2062430
DrugBank: Solanezumab (DB11756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks
Study: NCT03660176
Drug: butyrate enemas + routine management
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml/kg volume of butyrate enemas in addition to the colonic irrigations
Study: NCT01500473
Drug: Desogestrel
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
Study: NCT03552380
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
Study: NCT03552380
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
Study: NCT03552380
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
Study: NCT03705429
Drug: TC-H x Paclitaxel (P) + Trastuzumab(T)
Normalized name: Paclitaxel
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy
Study: NCT01801904
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
Study: NCT00153972
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02215967
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
Study: NCT00378144
Drug: Pseudoephedrine/Paracetamol
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]
Study: NCT03959969
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
Study: NCT02471040
Drug: Beta-hydroxybutyrate
Normalized name: L-alpha-amino-beta-hydroxybutyric acid
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
Study: NCT00739063
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
Study: NCT02201784
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of Equipotent doses
Study: NCT02201784
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of equipotent doses
Study: NCT00016081
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02046603
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
Study: NCT02461160
Drug: TAK-915 suspension
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-915 oral suspension
Study: NCT02461160
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam oral solution
Study: NCT02461160
Drug: TAK-915 tablet
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-915 tablet
Study: NCT02854527
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT02854527
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT02854527
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose
Study: NCT02854527
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
Study: NCT02854527
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
Study: NCT02854527
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
Study: NCT02065076
Drug: Sodium polystyrene sulfonate
Normalized name: Sodium Polystyrene Sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03065192
Drug: VY-AADC01
Normalized name: VY-HTT01
DrugBank: VY-HTT01 (DB16999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, neurosurgically infused, bilaterally into the striatum.
Study: NCT00367302
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: maintenance
Study: NCT00367302
Drug: methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintenance
Study: NCT01373138
Drug: Desloratadine and pseudoephedrine
Normalized name: Desloratadine and pseudoephedrine only product
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine and pseudoephedrine 5/240 mg
Study: NCT00018538
Drug: calcifidiol
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no